A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Exagen Inc. XGN
Promising (early) broader-coverage candidate · Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE bran
On FrontierLab's discovery record since 2026-08-04 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-05), not the curated Frontier signal.
⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.
⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.
Key quality signals
| Revenue growth (YoY) | 20.8% |
|---|---|
| Gross margin | 58.6% |
| Gross profits / assets | 0.8 |
| Rule of 40 | 2.2 |
| Net margin | -18.6% |
| Cash runway (months) | 45.4 |
| PEG | — |
| Price / sales | 2.2 |
Quality checklist
- ✓ Revenue growth — 20.8% (pass ≥ 20%)
- ✓ Capital efficiency
- ~ Gross margin — 58.6% (pass ≥ 60%)
- ~ Gross-margin trend — -0.8 (pass ≥ 2)
- ✓ Share dilution — 14.6%
Fundamentals — snapshot as of 2026-08-05
| Stage | Early |
|---|---|
| Share issuance (YoY) | 14.6% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-0.82 |
| Burn multiple | 0.1 |
| Gross-margin trend (pts) | -0.8 |
| Cash / assets | 0.47 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-08-05, not current
| Price at surface | $6.45 (as of 2026-08-05) |
|---|---|
| 52-week range | $2.59 – $12.23 |
| % off 52-wk high | -47.3% |
| RSI (14) | 74 |
| Relative volume | 7.3× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-05 (end-of-day). How grades are computed →